Celldex Therapeutics, Inc. (CLDX) research
Celldex Therapeutics, Inc.- Sector
- Biotechnology
- Last price
- $33.51
- As of
Celldex Therapeutics, Inc. (CLDX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.
As of . Source: SEC EDGAR filings for CLDX. Method and limitations.
Share the CLDX intelligence card
See CLDX live in the terminal
Track CLDX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CLDX terminal, freeActive signals for CLDX
- highCONSENSUS_BUY
4 tracked funds increased CLDX this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 100% of CLDX (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 100% of CLDX (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 96% of CLDX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +88% to CLDX (2026Q2)
FREE, NO ACCOUNT
Every signal on CLDX, as it fires
You are seeing 5 of 27 signals recorded on CLDX since 2026-05-30.
The five above landed across 2 days. The other 22 were recorded on 3 other days. 23 of the 27 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CLDX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 15117B202 · 2026Q2 | $43.6M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 15117B202 · 2026Q2 | $24.6M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 15117B202 · 2026Q2 | $4.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 15117B202 · 2026Q2 | $663K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CLDX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
CLDX against its peers
CLDX's operating margin of -18599.8% ranks in the 3rd percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | CLDX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.5M USD | 70.8M USD | 14 | 17 |
| Operating margin | -18599.8% | -382.0% | 3 | 15 |
| Net margin | -16748.0% | -314.9% | 3 | 15 |
| Return on equity | -49.1% | -31.7% | 38 | 24 |
Peers (24): QURE, MBX, ARQT, RCUS, VCYT, ZLAB, DNLI, ATAI, IMNM, DYN, PHVS, VKTX, GRTX, PGEN, LEGN, NAMS, NRIX, IRON, MLYS, GRAL, IDYA, VRDN, VERA, BEAM. Left out: ZLDPF (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CLDX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CLDX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CLDXand get the insider, 13F, options, and confluence read in one view.